董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Katherine Wolf | 女 | External director | 49 | 未披露 | 未持股 | 2016-04-19 |
| Yuval Yanai | 男 | External director | 63 | 未披露 | 未持股 | 2016-04-19 |
| Zeev Bronfeld | 男 | Director | 65 | 未披露 | 未持股 | 2016-04-19 |
| David Ben Ami | 男 | Director | 55 | 19.20万 | 未持股 | 2016-04-19 |
| Ranan Grobman | 男 | Director | 39 | 未披露 | 未持股 | 2016-04-19 |
| Tomer Kariv | 男 | Chairman of the Board of Directors | 54 | 未披露 | 未持股 | 2016-04-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nissim Mashiach | 男 | President and Chief Executive Officer | 55 | 39.00万 | 未持股 | 2016-04-19 |
| Shai Lankry | 男 | Chief Financial Officer | 39 | 46.23万 | 未持股 | 2016-04-19 |
董事简历
中英对照 | 中文 | 英文- Katherine Wolf
-
Katherine Wolf在该招股章程发布之日加入我司董事会。Wolf女士从2014年1月开始担任Rocket Science Healthcare LLC的首席执行官、联合创始人与合伙人。从2012年9月到2014年1月，Wolf女士提供独立的咨询服务。从2008年9月到2012年8月，Wolf女士在视觉科学公司（Vision-Sciences）的公司发展部担任首席财务官和执行副总裁，这是一家软式内视镜行业的纳斯达克上市的医疗设备公司。从2005年6月到2008年4月，Wolf女士担任汇丰证券美国公司（HSBC Securities USA Inc.）的投资银行业务部门的常务董事，她是该公司的医疗保健事业部的成员，并经营投资银行医疗用纺织品业务。加入汇丰银行（HSBC）前，从2000年到2005年，她在贝尔斯登公司（Bear, Stearns & Co.）的医疗保健事业部任职，晋升至常务董事。Wolf女士在哈佛商学院（Harvard Business School）获得工商管理硕士学位，并在威廉姆斯学院（Williams College）获得文学学士学位。
Katherine Wolf joined our Board effective upon the listing of our ordinary shares on NASDAQ. Since April 2015 Ms. Wolf has served as a partner at Ondra Partners, a financial advisory firm providing capital structuring, M&A and strategic advisory services. Prior thereto, Ms. Wolf was the Chief Executive Officer, Co-Founder and Partner of Rocket Science Healthcare LLC from January 2014 to March 2015 and from September 2012 to January 2014 she provided independent consulting services. From 2008 to August 2012 Ms. Wolf was the Chief Financial Officer and Executive Vice President, Corporate Development at Vision-Sciences, Inc., a NASDAQ-listed medical device company in the flexible endoscopy space. From 2005 to 2008 Ms. Wolf was a Managing Director at HSBC Securities USA Inc. in its investment banking division, where she was a member of the firm’s Health Care Group and ran the investment banking MedTech effort. Prior to HSBC, she worked at Bear, Stearns & Co. from 2000 to 2005 in the Health Care Group, most recently as a Managing Director. Ms. Wolf holds an M.B.A. from Harvard Business School and a B.A. from Williams College. - Katherine Wolf在该招股章程发布之日加入我司董事会。Wolf女士从2014年1月开始担任Rocket Science Healthcare LLC的首席执行官、联合创始人与合伙人。从2012年9月到2014年1月，Wolf女士提供独立的咨询服务。从2008年9月到2012年8月，Wolf女士在视觉科学公司（Vision-Sciences）的公司发展部担任首席财务官和执行副总裁，这是一家软式内视镜行业的纳斯达克上市的医疗设备公司。从2005年6月到2008年4月，Wolf女士担任汇丰证券美国公司（HSBC Securities USA Inc.）的投资银行业务部门的常务董事，她是该公司的医疗保健事业部的成员，并经营投资银行医疗用纺织品业务。加入汇丰银行（HSBC）前，从2000年到2005年，她在贝尔斯登公司（Bear, Stearns & Co.）的医疗保健事业部任职，晋升至常务董事。Wolf女士在哈佛商学院（Harvard Business School）获得工商管理硕士学位，并在威廉姆斯学院（Williams College）获得文学学士学位。
- Katherine Wolf joined our Board effective upon the listing of our ordinary shares on NASDAQ. Since April 2015 Ms. Wolf has served as a partner at Ondra Partners, a financial advisory firm providing capital structuring, M&A and strategic advisory services. Prior thereto, Ms. Wolf was the Chief Executive Officer, Co-Founder and Partner of Rocket Science Healthcare LLC from January 2014 to March 2015 and from September 2012 to January 2014 she provided independent consulting services. From 2008 to August 2012 Ms. Wolf was the Chief Financial Officer and Executive Vice President, Corporate Development at Vision-Sciences, Inc., a NASDAQ-listed medical device company in the flexible endoscopy space. From 2005 to 2008 Ms. Wolf was a Managing Director at HSBC Securities USA Inc. in its investment banking division, where she was a member of the firm’s Health Care Group and ran the investment banking MedTech effort. Prior to HSBC, she worked at Bear, Stearns & Co. from 2000 to 2005 in the Health Care Group, most recently as a Managing Director. Ms. Wolf holds an M.B.A. from Harvard Business School and a B.A. from Williams College.
- Yuval Yanai
-
Yuval Yanai在该招股章程发布之日加入我司董事会。从2005年9月到2014年3月，Yanai先生担任基文影像公司（Given Imaging Ltd.）的高级副总裁兼首席财务官。从2000年10月到2005年8月，他担任库尔工业公司（Koor Industries Ltd.）的高级副总裁兼首席财务官，其为以色列最大的控股公司之一。在这之前，从1998年4月到2000年9月，他担任NICE Systems Ltd.的副总裁兼首席财务官，这是一家以色列的交互洞察（Insight from Interactions）系统的全球供应商，从1991年到1998年4月，他担任爱尔新特公司（Elscint Ltd.）的财务部副总裁兼首席财务官，这是一家致力于医疗成像设备制造的前以色列公司，其被该行业规模更大的公司收购。他于1985年加入Elscint，并担任公司财务总管与公司财务主管至1991年。在这之前，Yanai先生担任Citycon Oj、Starplast Industries Ltd.、 Adama Ltd.（以前该公司叫Makteshim-Agan Industries Ltd.)、 ECI Telecom Ltd.、Equity One, Inc.、 BVR Systems Ltd.、Tadiran Communication Ltd.、 The Elisra Group与Telrad Networks Ltd.。Yanai先生在特拉维夫大学（Tel-Aviv University）获得会计学与经济学理学学士学位。
Yuval Yanai has served as a member of our Board of Directors since March 2015 and has served as the Chairman of our Audit Committee and Compensation Committee since March 2015 as the Chairman of our Nominating Committee since October 2015 and as the Chairman of our Financing Committee since June 2016. Mr. Yanai served as Senior Vice President and Chief Financial Officer of Given Imaging Ltd. from September 2005 through March 2014. From October 2000 through August 2005 Mr. Yanai served as Senior Vice President and Chief Financial Officer of Koor Industries Ltd. Prior to that, from April 1998 to September 2000 Mr. Yanai served as Vice President and Chief Financial Officer of NICE Systems Ltd., an Israeli global provider of Insight from Interactions, and, from 1991 to April 1998 he served as the Vice President, Finance and Chief Financial Officer of Elscint Ltd., a former Israeli company engaged in the developing and manufacturing of medical imaging devices. Mr. Yanai joined Elscint in 1985 and served as Corporate Controller and Corporate Treasurer through 1991. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of Hadassah Medical Organization, and serves as the Chairman of its finance and compensation committees and as a member of its tenders and donation committee. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of S&P Global Maalot. Mr. Yanai also serves as an external director (within the meaning of the Israeli Companies Law) of Clal Biotechnology Industries and serves as the Chairman of its audit and financial reporting committees, and as a member of its compensation committee. Mr. Yanai also serves as a member of the board of directors of Nobio Ltd. and BRH Medical Ltd. Previously, Mr. Yanai served as an external director (within the meaning of the Israeli Companies Law) of Mazor Robotics Ltd. and Medical Compression Systems Ltd. and as a director of Medigus Ltd. Mr. Yanai also served as a director of Macrocure Ltd., Citycon Oj, Starplast Industries Ltd., Adama Ltd. (formerly Makteshim-Agan Industries Ltd.), ECI Telecom Ltd., Equity One, Inc., BVR Systems Ltd., Tadiran Communication Ltd., The Elisra Group, Telrad Networks Ltd. and Medical Compression Systems (D.B.N) Ltd. Mr. Yanai holds a B.Sc. degree in Accounting and Economics from Tel-Aviv University. - Yuval Yanai在该招股章程发布之日加入我司董事会。从2005年9月到2014年3月，Yanai先生担任基文影像公司（Given Imaging Ltd.）的高级副总裁兼首席财务官。从2000年10月到2005年8月，他担任库尔工业公司（Koor Industries Ltd.）的高级副总裁兼首席财务官，其为以色列最大的控股公司之一。在这之前，从1998年4月到2000年9月，他担任NICE Systems Ltd.的副总裁兼首席财务官，这是一家以色列的交互洞察（Insight from Interactions）系统的全球供应商，从1991年到1998年4月，他担任爱尔新特公司（Elscint Ltd.）的财务部副总裁兼首席财务官，这是一家致力于医疗成像设备制造的前以色列公司，其被该行业规模更大的公司收购。他于1985年加入Elscint，并担任公司财务总管与公司财务主管至1991年。在这之前，Yanai先生担任Citycon Oj、Starplast Industries Ltd.、 Adama Ltd.（以前该公司叫Makteshim-Agan Industries Ltd.)、 ECI Telecom Ltd.、Equity One, Inc.、 BVR Systems Ltd.、Tadiran Communication Ltd.、 The Elisra Group与Telrad Networks Ltd.。Yanai先生在特拉维夫大学（Tel-Aviv University）获得会计学与经济学理学学士学位。
- Yuval Yanai has served as a member of our Board of Directors since March 2015 and has served as the Chairman of our Audit Committee and Compensation Committee since March 2015 as the Chairman of our Nominating Committee since October 2015 and as the Chairman of our Financing Committee since June 2016. Mr. Yanai served as Senior Vice President and Chief Financial Officer of Given Imaging Ltd. from September 2005 through March 2014. From October 2000 through August 2005 Mr. Yanai served as Senior Vice President and Chief Financial Officer of Koor Industries Ltd. Prior to that, from April 1998 to September 2000 Mr. Yanai served as Vice President and Chief Financial Officer of NICE Systems Ltd., an Israeli global provider of Insight from Interactions, and, from 1991 to April 1998 he served as the Vice President, Finance and Chief Financial Officer of Elscint Ltd., a former Israeli company engaged in the developing and manufacturing of medical imaging devices. Mr. Yanai joined Elscint in 1985 and served as Corporate Controller and Corporate Treasurer through 1991. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of Hadassah Medical Organization, and serves as the Chairman of its finance and compensation committees and as a member of its tenders and donation committee. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of S&P Global Maalot. Mr. Yanai also serves as an external director (within the meaning of the Israeli Companies Law) of Clal Biotechnology Industries and serves as the Chairman of its audit and financial reporting committees, and as a member of its compensation committee. Mr. Yanai also serves as a member of the board of directors of Nobio Ltd. and BRH Medical Ltd. Previously, Mr. Yanai served as an external director (within the meaning of the Israeli Companies Law) of Mazor Robotics Ltd. and Medical Compression Systems Ltd. and as a director of Medigus Ltd. Mr. Yanai also served as a director of Macrocure Ltd., Citycon Oj, Starplast Industries Ltd., Adama Ltd. (formerly Makteshim-Agan Industries Ltd.), ECI Telecom Ltd., Equity One, Inc., BVR Systems Ltd., Tadiran Communication Ltd., The Elisra Group, Telrad Networks Ltd. and Medical Compression Systems (D.B.N) Ltd. Mr. Yanai holds a B.Sc. degree in Accounting and Economics from Tel-Aviv University.
- Zeev Bronfeld
-
Zeev Bronfeld，自2010年以来，是本公司的临时董事长；自1996年以来，是Protalix有限公司的一位董事；自2006年12月31日以来，是本公司的一位董事。他是一个在许多生物技术公司工作的有经验的商人。他是以色列一家专营生物技术公司的上市控股公司- Biocell有限公司（TASE：BCEL）的联合创始人，以及自1986年以来担任该公司的首席执行官。他是Biocell有限公司的一位董事；是D.N.A. Biomedical Solutions 有限公司 （TASE： DNA） 的董事长（这两家公司都是在TASE交易的上市公司）。他还是许多私营公司的一位董事，这些公司中大部分都从事生命科学事务，比如The Trendlines集团和Macrocure有限公司。2004-2012年期间，是一家在他的职业生涯后期在Nasdaq和TASE上市的公司- D. Medical Industries有限公司的一位董事。他是于1975年从Hebrew大学获得他的经济学学士学位的。
Zeev Bronfeld,has served as the Chairman of Protalix Biotherapeutics, Inc. Board of Directors since August 2019. He has served as a director of Protalix Ltd., Protalix Biotherapeutics, Inc. wholly-owned subsidiary and sole operating unit, since 1996 and as Protalix Biotherapeutics, Inc. director since December 2006. He was a co-founder of Bio-cell Ltd., a former Israeli publicly-traded holding company that specialized in biotechnology companies and served as its Chief Executive Officer from 1986 through 2015. Mr. Bronfeld serves as a director of The Trendlines Group (SGX:42T), a company listed on the Singapore Exchange. Mr. Bronfeld is also a director of a number of privately-held companies, most of which are involved in the life sciences industry, such as Contipi Medical Ltd. From April 2017 through November 2022 Mr. Bronfeld served as a director of Electreon Wireless Ltd. (TASE:ELWS) (formerly, Biomedix Incubator Ltd.), from August 2010 through April 2021, he served as a director of Entera Bio Ltd. (NASDAQ: ENTX), and from November 2009 through February 2021, he served as a director of D.N.A. Biomedical Solutions Ltd. (TASE:DNA) and from January 2008 through January 2017, he served as a director of Macrocure Ltd., a Nasdaq-listed company that merged into Leap Therapeutics, Inc. (NASDAQ:LPTX). Mr. Bronfeld received a B.A. in Economics from the Hebrew University in 1975. - Zeev Bronfeld，自2010年以来，是本公司的临时董事长；自1996年以来，是Protalix有限公司的一位董事；自2006年12月31日以来，是本公司的一位董事。他是一个在许多生物技术公司工作的有经验的商人。他是以色列一家专营生物技术公司的上市控股公司- Biocell有限公司（TASE：BCEL）的联合创始人，以及自1986年以来担任该公司的首席执行官。他是Biocell有限公司的一位董事；是D.N.A. Biomedical Solutions 有限公司 （TASE： DNA） 的董事长（这两家公司都是在TASE交易的上市公司）。他还是许多私营公司的一位董事，这些公司中大部分都从事生命科学事务，比如The Trendlines集团和Macrocure有限公司。2004-2012年期间，是一家在他的职业生涯后期在Nasdaq和TASE上市的公司- D. Medical Industries有限公司的一位董事。他是于1975年从Hebrew大学获得他的经济学学士学位的。
- Zeev Bronfeld,has served as the Chairman of Protalix Biotherapeutics, Inc. Board of Directors since August 2019. He has served as a director of Protalix Ltd., Protalix Biotherapeutics, Inc. wholly-owned subsidiary and sole operating unit, since 1996 and as Protalix Biotherapeutics, Inc. director since December 2006. He was a co-founder of Bio-cell Ltd., a former Israeli publicly-traded holding company that specialized in biotechnology companies and served as its Chief Executive Officer from 1986 through 2015. Mr. Bronfeld serves as a director of The Trendlines Group (SGX:42T), a company listed on the Singapore Exchange. Mr. Bronfeld is also a director of a number of privately-held companies, most of which are involved in the life sciences industry, such as Contipi Medical Ltd. From April 2017 through November 2022 Mr. Bronfeld served as a director of Electreon Wireless Ltd. (TASE:ELWS) (formerly, Biomedix Incubator Ltd.), from August 2010 through April 2021, he served as a director of Entera Bio Ltd. (NASDAQ: ENTX), and from November 2009 through February 2021, he served as a director of D.N.A. Biomedical Solutions Ltd. (TASE:DNA) and from January 2008 through January 2017, he served as a director of Macrocure Ltd., a Nasdaq-listed company that merged into Leap Therapeutics, Inc. (NASDAQ:LPTX). Mr. Bronfeld received a B.A. in Economics from the Hebrew University in 1975.
- David Ben Ami
-
David Ben Ami，董事长、共同创始人；自本公司2008年初成立之时起，担任董事。他在生命科学行业有着20多年的管理、业务开发、企业战略方面的经验。2005年6月至2010年4月，他担任NVR Labs的首席执行官；2003年6月至2005年5月，担任Boston Scientific Israel的国家总监；1999年1月至2003年6月，担任Teva Israel的业务开发总监。他目前是BioCell Ltd.、Degania Silicone Ltd.、Entera Bio Ltd及其它医疗器械、制药公司的董事。他在Tel-Aviv University获得经济与管理专业的工商管理硕士学位、学士学位。
David Ben Ami has served as a member of our board of directors since 2014. Mr. Ben Ami is the Managing Partner of Corundum Open Innovation Fund, a life sciences venture capital fund, and the Executive Investment Director of SBI JI Innovation Advisory Ltd. Mr. Ben Ami has more than 25 years of experience with activities in management, business development, corporate strategy and investments in the life sciences industry. He served as chief executive officer of NVR Labs Ltd. from 2005 to 2010 Israeli Country Manager of Boston Scientific, Israel from 2003 to 2005 and director of business development of Teva Israel and Teva Medical from 1999 to 2002. In 2008 he founded Macrocure Ltd., and served as the chairman of the board of directors of Macrocure from 2008 until 2016. Mr. Ben Ami currently serves, and in the past served as a board member in numerous companies including: Immunobrain Checkpoint Inc., Novolog Ltd., Degania Medical Ltd., Biocell Ltd., Meytav Technology Incubator, Hairstetics Ltd., VVT Medical and Contipi Medical Ltd. He received his M.B.A. and B.A. in Economics & Management from Tel-Aviv University. Mr. Ben Ami serves on our board of directors as a designee of the Centillion Fund pursuant to rights granted to Centillion Fund under our articles of association as in effect prior to the closing of this offering. For further information regarding our commitment under certain circumstances to nominate one director nominee designated by Centillion Fund following the closing of this offering, see “- Arrangements for Election of Directors.” Following the consummation of this offering, Mr. Ben Ami intends to resign from our board. - David Ben Ami，董事长、共同创始人；自本公司2008年初成立之时起，担任董事。他在生命科学行业有着20多年的管理、业务开发、企业战略方面的经验。2005年6月至2010年4月，他担任NVR Labs的首席执行官；2003年6月至2005年5月，担任Boston Scientific Israel的国家总监；1999年1月至2003年6月，担任Teva Israel的业务开发总监。他目前是BioCell Ltd.、Degania Silicone Ltd.、Entera Bio Ltd及其它医疗器械、制药公司的董事。他在Tel-Aviv University获得经济与管理专业的工商管理硕士学位、学士学位。
- David Ben Ami has served as a member of our board of directors since 2014. Mr. Ben Ami is the Managing Partner of Corundum Open Innovation Fund, a life sciences venture capital fund, and the Executive Investment Director of SBI JI Innovation Advisory Ltd. Mr. Ben Ami has more than 25 years of experience with activities in management, business development, corporate strategy and investments in the life sciences industry. He served as chief executive officer of NVR Labs Ltd. from 2005 to 2010 Israeli Country Manager of Boston Scientific, Israel from 2003 to 2005 and director of business development of Teva Israel and Teva Medical from 1999 to 2002. In 2008 he founded Macrocure Ltd., and served as the chairman of the board of directors of Macrocure from 2008 until 2016. Mr. Ben Ami currently serves, and in the past served as a board member in numerous companies including: Immunobrain Checkpoint Inc., Novolog Ltd., Degania Medical Ltd., Biocell Ltd., Meytav Technology Incubator, Hairstetics Ltd., VVT Medical and Contipi Medical Ltd. He received his M.B.A. and B.A. in Economics & Management from Tel-Aviv University. Mr. Ben Ami serves on our board of directors as a designee of the Centillion Fund pursuant to rights granted to Centillion Fund under our articles of association as in effect prior to the closing of this offering. For further information regarding our commitment under certain circumstances to nominate one director nominee designated by Centillion Fund following the closing of this offering, see “- Arrangements for Election of Directors.” Following the consummation of this offering, Mr. Ben Ami intends to resign from our board.
- Ranan Grobman
-
Ranan Grobman，2012年5月起，担任本公司董事。过去的14年里，他是以色列高科技公司的活跃投资者。他从2008年起，担任Jerusalem Global Ventures的普通合伙人；1998年以来，在该公司担任过多个职务。2010年以来，他通过JGV担任Vaizra Ventures的顾问，这是本公司的股东。2006-2008，他担任Certagon的业务开发副总裁；1999-2001，担任Yazam的投资银行副总裁。
Ranan Grobman has served on our Board of Directors since May 2012. Mr. Grobman has been an active investor in Israeli high-tech companies for the last 14 years. Mr. Grobman has served as a general partner of Jerusalem Global Ventures, or JGV, since 2008 and has served in different capacities since 1998. Mr. Grobman, through JGV, serves as an advisor to Vaizra Ventures, a shareholder of our company since 2010. Mr. Grobman served as Vice President of Business Development at Certagon from 2006 to 2008 and Vice President Investment Banking at Yazam from 1999 to 2001. - Ranan Grobman，2012年5月起，担任本公司董事。过去的14年里，他是以色列高科技公司的活跃投资者。他从2008年起，担任Jerusalem Global Ventures的普通合伙人；1998年以来，在该公司担任过多个职务。2010年以来，他通过JGV担任Vaizra Ventures的顾问，这是本公司的股东。2006-2008，他担任Certagon的业务开发副总裁；1999-2001，担任Yazam的投资银行副总裁。
- Ranan Grobman has served on our Board of Directors since May 2012. Mr. Grobman has been an active investor in Israeli high-tech companies for the last 14 years. Mr. Grobman has served as a general partner of Jerusalem Global Ventures, or JGV, since 2008 and has served in different capacities since 1998. Mr. Grobman, through JGV, serves as an advisor to Vaizra Ventures, a shareholder of our company since 2010. Mr. Grobman served as Vice President of Business Development at Certagon from 2006 to 2008 and Vice President Investment Banking at Yazam from 1999 to 2001.
- Tomer Kariv
-
Tomer Kariv，2008年3月加入本公司。他是Pontifax的共同创始人、首席执行官，这是以色列的生命科学行业投资基金集团，也是本公司的股东，专注于发展阶段的生物制药公司、医疗科技公司的投资。他目前在该基金的许多投资组合公司中担任董事，其中包括：Check-Cap Ltd的董事长、Arno Therapeutics的董事。加入Pontifax之前的10年，他在许多技术驱动型企业、初创企业的投资、管理、培育工作中，发挥了重要的作用；还在以色列顶尖的金融机构担任过高级管理职务。他在纽约的Sullivan & Cromwell从事过法律执业；在Harvard University获得经济学士学位，在Harvard Law School获得法律博士学位。
Tomer Kariv is the Chairman of our Board and previously served as a member of the board of directors of Eloxx Pharmaceuticals, Ltd. the “Eloxx Limited Board” since October 2016. For the past 14 years Mr. Kariv has been the Chief Executive Officer and Co-Founder of The Pontifax Group, which established six funds with over $1 billion under management and invested in over 100 portfolio companies. Mr. Kariv also serves on the board of directors of many of The Pontifax Group's portfolio companies including: V-Wave Ltd., EyeYon Medical Ltd., Cathworks Ltd., Raziel Therapeutics Ltd. and Keros Therapeutics, Inc. (a public biotech company where Mr. Kariv serves as chair of the nominating and corporate governance committee). He previously served as a Director of VBI Vaccines Inc., 89Bio Ltd., LogicBio, Entera Ltd., Nutrinia Ltd., Check-Cap Ltd., Headsense Medical Ltd., Macrocure Ltd., Avraham Pharmaceuticals, Stimatix Ltd., Applied Immune Technologies, and Otic Pharma Ltd. Mr. Kariv has 15 years of experience as a seasoned venture capital industry executive and has played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv received a B.A. in Economics from Harvard University and a Juris Doctor from Harvard Law School. - Tomer Kariv，2008年3月加入本公司。他是Pontifax的共同创始人、首席执行官，这是以色列的生命科学行业投资基金集团，也是本公司的股东，专注于发展阶段的生物制药公司、医疗科技公司的投资。他目前在该基金的许多投资组合公司中担任董事，其中包括：Check-Cap Ltd的董事长、Arno Therapeutics的董事。加入Pontifax之前的10年，他在许多技术驱动型企业、初创企业的投资、管理、培育工作中，发挥了重要的作用；还在以色列顶尖的金融机构担任过高级管理职务。他在纽约的Sullivan & Cromwell从事过法律执业；在Harvard University获得经济学士学位，在Harvard Law School获得法律博士学位。
- Tomer Kariv is the Chairman of our Board and previously served as a member of the board of directors of Eloxx Pharmaceuticals, Ltd. the “Eloxx Limited Board” since October 2016. For the past 14 years Mr. Kariv has been the Chief Executive Officer and Co-Founder of The Pontifax Group, which established six funds with over $1 billion under management and invested in over 100 portfolio companies. Mr. Kariv also serves on the board of directors of many of The Pontifax Group's portfolio companies including: V-Wave Ltd., EyeYon Medical Ltd., Cathworks Ltd., Raziel Therapeutics Ltd. and Keros Therapeutics, Inc. (a public biotech company where Mr. Kariv serves as chair of the nominating and corporate governance committee). He previously served as a Director of VBI Vaccines Inc., 89Bio Ltd., LogicBio, Entera Ltd., Nutrinia Ltd., Check-Cap Ltd., Headsense Medical Ltd., Macrocure Ltd., Avraham Pharmaceuticals, Stimatix Ltd., Applied Immune Technologies, and Otic Pharma Ltd. Mr. Kariv has 15 years of experience as a seasoned venture capital industry executive and has played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv received a B.A. in Economics from Harvard University and a Juris Doctor from Harvard Law School.
高管简历
中英对照 | 中文 | 英文- Nissim Mashiach
Nissim Mashiach，2012年6月起，担任本公司的总裁、首席执行官。加入本公司之前，2009-2012，他是Johnson & Johnson旗下Ethicon的总经理。此前，他是Omrix Biopharmaceuticals的总裁、首席运营官，该公司在2008年被Johnson & Johnson收购。加入Omrix之前，他在一些制药公司担任过领导职务。他在英格兰University of Manchester获得工商管理硕士学位、在以色列耶路撒冷的Hebrew University获得药学硕士学位，在以色列海法的Technion-Israel Institute of Technology获得化学工程学士学位。
Nissim Mashiach has served as a member of our board of directors since June 2017. Mr. Mashiach served as President and Chief Executive Officer of Macrocure Ltd., a Nasdaq‑listed biotechnology company focused on the treatment of chronic and other hard‑to‑heal wounds, from June 2012 to January 2017. From 2009 to 2012 he served as General Manager at Ethicon, a Johnson & Johnson company. Prior to Ethicon, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson & Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership positions at several pharmaceutical companies. He holds an MBA from the University of Manchester in Manchester, England, an MPharmSc from the Hebrew University in Jerusalem, Israel, and a B.Sc, Chemical Engineering from the Technion‑Israel Institute of Technology in Haifa, Israel.- Nissim Mashiach，2012年6月起，担任本公司的总裁、首席执行官。加入本公司之前，2009-2012，他是Johnson & Johnson旗下Ethicon的总经理。此前，他是Omrix Biopharmaceuticals的总裁、首席运营官，该公司在2008年被Johnson & Johnson收购。加入Omrix之前，他在一些制药公司担任过领导职务。他在英格兰University of Manchester获得工商管理硕士学位、在以色列耶路撒冷的Hebrew University获得药学硕士学位，在以色列海法的Technion-Israel Institute of Technology获得化学工程学士学位。
- Nissim Mashiach has served as a member of our board of directors since June 2017. Mr. Mashiach served as President and Chief Executive Officer of Macrocure Ltd., a Nasdaq‑listed biotechnology company focused on the treatment of chronic and other hard‑to‑heal wounds, from June 2012 to January 2017. From 2009 to 2012 he served as General Manager at Ethicon, a Johnson & Johnson company. Prior to Ethicon, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson & Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership positions at several pharmaceutical companies. He holds an MBA from the University of Manchester in Manchester, England, an MPharmSc from the Hebrew University in Jerusalem, Israel, and a B.Sc, Chemical Engineering from the Technion‑Israel Institute of Technology in Haifa, Israel.
- Shai Lankry
Shai Lankry，2013年12月起，担任本公司的首席财务官、以色列地区经理。2006-2013，他任职于Johnson & Johnson旗下Ethicon Biosurgery的分部Omrix Biopharmaceuticals, Inc，最后的职务是生物集群财务总监，管理着全球各地的生物业务财务机构。此前，2004-2006，他是Kesselman & Kesselman审计业务的高级助理，专门从事高科技行业相关业务，这是PriceWaterhouseCoopers International Limited的成员公司。他是一名注册会计师，在以色列的Tel-Aviv University获得财务方向的工商管理硕士学位。
Shai Lankry has served as our Chief Financial Officer since April 2018. Mr. Lankry has more than 15 years of senior management experience in finance. Prior to joining Gamida Cell, from 2016 to 2018 Mr. Lankry served as a Finance Director at West Pharmaceutical Services Inc., leading the R&D and operations financials for the Israeli subsidiary. From 2013 to 2017 Mr. Lankry was the Chief Financial Officer and Israeli Site Manager of Macrocure Ltd. where he played an integral role in the company’s 2014 U.S. initial public offering and 2017 acquisition by Leap Therapeutics Inc. From 2006 to 2013 Mr. Lankry held senior finance positions at Ethicon Biosurgery, a Johnson & Johnson company, where in his most recent position, he was the Biologics Cluster Finance Director, managing the Biologics finance organization at multiple sites worldwide. Mr. Lankry is a licensed Israeli CPA and holds an M.B.A. in Finance from Tel-Aviv University.- Shai Lankry，2013年12月起，担任本公司的首席财务官、以色列地区经理。2006-2013，他任职于Johnson & Johnson旗下Ethicon Biosurgery的分部Omrix Biopharmaceuticals, Inc，最后的职务是生物集群财务总监，管理着全球各地的生物业务财务机构。此前，2004-2006，他是Kesselman & Kesselman审计业务的高级助理，专门从事高科技行业相关业务，这是PriceWaterhouseCoopers International Limited的成员公司。他是一名注册会计师，在以色列的Tel-Aviv University获得财务方向的工商管理硕士学位。
- Shai Lankry has served as our Chief Financial Officer since April 2018. Mr. Lankry has more than 15 years of senior management experience in finance. Prior to joining Gamida Cell, from 2016 to 2018 Mr. Lankry served as a Finance Director at West Pharmaceutical Services Inc., leading the R&D and operations financials for the Israeli subsidiary. From 2013 to 2017 Mr. Lankry was the Chief Financial Officer and Israeli Site Manager of Macrocure Ltd. where he played an integral role in the company’s 2014 U.S. initial public offering and 2017 acquisition by Leap Therapeutics Inc. From 2006 to 2013 Mr. Lankry held senior finance positions at Ethicon Biosurgery, a Johnson & Johnson company, where in his most recent position, he was the Biologics Cluster Finance Director, managing the Biologics finance organization at multiple sites worldwide. Mr. Lankry is a licensed Israeli CPA and holds an M.B.A. in Finance from Tel-Aviv University.